Medicines update: insulin pumps
Long-term control is measured using haemoglobin A1c (HbA1C) levels and time in range (time spent with SGC 3.9–10 mmol/L).1 Conventionally, insulin has been delivered by multiple daily injections of insulin (MDI) with both rapid-acting and long-acting insulin tailored to activity and food intake. In...
Saved in:
Published in | Archives of disease in childhood. Education and practice edition p. edpract-2023-326184 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
29.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Long-term control is measured using haemoglobin A1c (HbA1C) levels and time in range (time spent with SGC 3.9–10 mmol/L).1 Conventionally, insulin has been delivered by multiple daily injections of insulin (MDI) with both rapid-acting and long-acting insulin tailored to activity and food intake. In 2008, the National Institute for Health and Care Excellence (NICE) reviewed evidence from multiple randomised controlled trials (RCTs) and observational studies, concluding that compared with MDI, CSII has quality of life benefits for CYP with T1DM such as flexibility and autonomy as well as improved socialisation and sleep. The 2023 NICE guideline regarding HCLS concludes that HCLS improve glycaemic control (when considering HbA1C levels and time in range) compared with CSII without integrated CGM, and are likely to reduce the burden of managing T1DM for CYP and their family/carers.2–6 This article aims to outline the general principles of CSII therapy and HCLS, enabling a general paediatrician to troubleshoot out-of-hours issues and manage patients with insulin pumps in hospital. The CYP/carer must direct the pump to deliver a bolus in anticipation of food intake, although many pumps have inbuilt bolus calculators to determine the appropriate number of units to deliver. |
---|---|
ISSN: | 1743-0585 1743-0593 |
DOI: | 10.1136/archdischild-2023-326184 |